Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood

Clin Cancer Res. 2009 Apr 1;15(7):2541-51. doi: 10.1158/1078-0432.CCR-08-2806. Epub 2009 Mar 24.

Abstract

Purpose: The aim of this study was to characterize the primary gp100(209-2M)-specific T-cell response in vaccine-draining, metastases-free lymph nodes and peripheral blood of peptide-vaccinated stage I to III melanoma patients.

Experimental design: After two or three gp100(209-2M) vaccinations, sentinel lymph nodes that drained both the primary tumor and adjacent vaccine sites were excised concomitant with wide excision of the tumor. Comparative 7-color flow cytometry phenotype analysis was done on gp100 tetramer-positive CD8(+) T cells from sentinel lymph nodes, closely proximate time-related peripheral blood mononuclear cells (PBMC) collected 2 to 4 weeks after sentinel lymph node excision, and on PBMC collected 6 months later after 7 or 11 more immunizations. Lymph node and peripheral blood T cells were tested for proliferative response, functional avidity, and tumor cell-induced CD107 mobilization.

Results: The frequencies of gp100-specific CD8(+) T cells from time-related PBMC and sentinel lymph nodes were comparable and were similar to those reported for virus-specific memory T cells. Their respective in vitro proliferation responses were also equivalent but statistically higher than proliferation responses of peripheral blood T cells collected after completion of the entire vaccine regimen. By contrast, functional avidity and CD107 responses were significantly higher in circulating T cells. Sentinel lymph node-derived, gp100-specific CD8(+) T cells predominantly expressed central and effector memory phenotype signatures, whereas there were higher frequencies of effector T cells in the peripheral blood.

Conclusion: Priming immunization with gp100(209-2M) without coadministration of CD4(+) helper T cell-restricted antigens induced the effective expansion of peptide-specific central and effector memory CD8(+) T cells with high proliferation potential in vaccine-draining lymph nodes of stage I to III melanoma patients. Lymph node memory T cells gave rise to circulating gp100-specific effector T cells exhibiting increased functional maturation.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / immunology*
  • Cancer Vaccines / immunology*
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Immunologic Memory
  • Lymph Nodes / immunology
  • Lymphocyte Activation
  • Lysosomal Membrane Proteins / analysis
  • Melanoma / immunology*
  • Melanoma / pathology
  • Membrane Glycoproteins / immunology*
  • Sentinel Lymph Node Biopsy
  • gp100 Melanoma Antigen

Substances

  • Cancer Vaccines
  • Histocompatibility Antigens Class I
  • Lysosomal Membrane Proteins
  • Membrane Glycoproteins
  • PMEL protein, human
  • gp100 Melanoma Antigen
  • gp100(209-2M) vaccine